Asterias Biotherapeutics Inc. Series A
AST
AST was delisted on the 7th of March, 2019.
0 hedge funds and large institutions have $0 invested in Asterias Biotherapeutics Inc. Series A in 2019 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 46 closing their positions.
100% less funds holding
Funds holding: 46 → 0 (-46)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
100% less capital invested
Capital invested by funds: $4.73M → $0 (-$4.73M)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 46
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
-$3.28M |
| 2 |
NFC
Northeast Financial Consultants
Westport,
Connecticut
|
-$358K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$251K |
| 4 |
Renaissance Technologies
New York
|
-$206K |
| 5 |
BlackRock
New York
|
-$131K |
AST Hedge Fund Activity: Q1 2019 in Review
0 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Asterias Biotherapeutics Inc. Series A (AST) for Q1 2019, worth a combined $0 — down 100% from $4.73M a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of AST and 0 opened new positions — a net loss of 46 holders — while 0 trimmed existing stakes and 0 added.
The largest seller was Broadwood Capital, exiting entirely with an estimated $3.28M sold.
- 0 institutional investors held Asterias Biotherapeutics Inc. Series A (AST) as of Q1 2019, down from 46 in Q4 2018.
- Funds reported $0 of Asterias Biotherapeutics Inc. Series A stock for Q1 2019, down 100% quarter-over-quarter.
- 0 funds opened new Asterias Biotherapeutics Inc. Series A positions in Q1 2019 and 46 closed out, a net change of -46 holders.
- The largest Asterias Biotherapeutics Inc. Series A seller in Q1 2019 was Broadwood Capital, an estimated $3.28M sold.
Based on aggregated 13F filings for Q1 2019.